p < 0.001), but there was no difference in intent-to-treat survival (70 AE 5% vs. 63 AE 5%; p ¼ 0.307). In the OMM arm, 23 of 103 (22%) received delayed LVADs (18 within 12 months; 5 from 12 to 24 months). LVAD adverse events declined after year 1 for bleeding (primarily gastrointestinal) and arrhythmias.
CONCLUSIONS Survival on original therapy with improvement in 6-min walk distance was superior with LVAD compared with OMM at 2 years. Reduction in key adverse events beyond 1 year was observed in the LVAD group. The ROADMAP trial provides risk-benefit information to guide patient-and physician-shared decision making for elective LVAD therapy as a treatment for heart failure. Starling et al.
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